#	Pagina
attuale pagina	/open-h2020/projects/227606/index.html

Opendata, web and dolomites

TARNEPC SIGNED

Targeting treatment-induced neuroendocrine prostate cancer

Total Cost €

EC-Contrib. €

Partnership

Views

TARNEPC project word cloud

Explore the words cloud of the TARNEPC project. It provides you a very rough idea of what is the project "TARNEPC" about.

health therapies antiandrogens group reduce castration service fuels independent resistant strategies desperately patient effect benefit patients utilized options drugs characterizing signaling significantly tumors deprivation disease cancer form genomics receptor stem neuronal block approximately neuroendocrine treatment generation adapt pathology therapy cell 25 curative completely metastases therapeutic aggressive prostate cells androgen tumor current

Project "TARNEPC" data sheet

The following table provides information about the project.

Coordinator	ITA-SUOMEN YLIOPISTO Organization address address: YLIOPISTONRANTA 1 E city: KUOPIO postcode: 70211 website: www.uef.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Finland [FI]
Total cost	202˙680 €
EC max contribution	202˙680 € (100%)
Programme	1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
Code Call	H2020-MSCA-IF-2019
Funding Scheme	MSCA-IF-EF-RI
Starting year	2021
Duration (year-month-day)	from 2021-01-01 to 2022-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ITA-SUOMEN YLIOPISTO ITA-SUOMEN YLIOPISTO Organization address address: YLIOPISTONRANTA 1 E city: KUOPIO postcode: 70211 website: www.uef.fi contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FI (KUOPIO)	coordinator	202˙680.00

Map

Project objective

Current treatment options for prostate cancer include use of androgen deprivation therapies to block tumor growth but often the tumors become castration-resistant. Even the second generation antiandrogens that do have significant effect on castration-resistant tumor growth in patients are not curative. Approximately 25% of prostate cancer patients with castration-resistant disease treated with antiandrogens develop a form of prostate cancer that is completely independent of androgen receptor signaling that fuels the tumor growth. Analyses of the pathology and genomics of these patient tumors has identified that the tumor cells adapt cancer stem cell and neuronal cell characteristics. Currently, there are no treatment options for this patient group. Thus, development of novel strategies including selection of drugs that could be used to reduce the tumor growth and metastases in this patient group are desperately needed. This project aims at characterizing a novel therapeutic target against aggressive, the treatment resistant neuroendocrine prostate cancer. The success of this project may significantly benefit prostate cancer patients and provide cost-effective therapy options to be utilized in health service.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TARNEPC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TARNEPC" are provided by the European Opendata Portal: CORDIS opendata.